Pharmaceutical Fraud Penalties: The Payment Is Only Part of the Consequence

Pharmaceutical fraud penalties can include damages, a penalty for each false claim, separate price-reporting penalties and exclusion from federal healthcare programs. A settlement can also change how a drug company pays its sales force, monitors speaker programs and certifies its compliance. If you work in sales, government pricing or compliance, the conduct behind those consequences may be familiar: a speaker chosen for prescriptions, a hospital discount missing from Best Price, or a rebate calculation management chose to keep using.

How Civil Pharmaceutical Fraud Penalties Work

The False Claims Act can require three times the government’s loss plus a penalty for each false claim. The Justice Department’s July 3, 2025 adjustment set the per-claim range at $14,308 to $28,619 for penalties assessed after that date. Its July 15, 2026 notice kept those amounts unchanged.

A manufacturer can cause a false claim even when a pharmacy or physician submits the bill. That connection matters in pharmaceutical cases. The sales representative’s payment, the manufacturer’s promotion and the prescription reimbursement may sit in different organizations, but the civil case connects them.

In September 2009, Pfizer agreed to a $1 billion civil settlement over allegations involving Bextra, Geodon, Zyvox and Lyrica. The government alleged that Pfizer promoted uses that federal health care programs did not cover and caused false claims for those uses. The settlement also addressed alleged payments to healthcare providers to induce prescribing. At the time, the Justice Department called it the largest civil fraud settlement against a pharmaceutical company.

The manufacturer was selling drugs. Other participants were billing the programs. According to the government’s allegations, taxpayers paid for prescriptions the programs did not cover.

A Separate Civil Remedy for Kickbacks

The Department of Health and Human Services’ Office of Inspector General also has its own civil monetary penalty authority. For a kickback violation, it permits an assessment of up to three times the payment or benefit offered, paid, requested or received. That amount measures the inducement itself, while False Claims Act damages measure the government’s loss.

A speaker-payment case can therefore raise different financial questions: what was paid to induce prescribing, and what government programs paid on the resulting claims. Keeping those questions separate gives the company’s payment records and the prescription claims their proper place in the case. The Inspector General can also order exclusion in the same proceeding.

A Settlement, a Recovery and a Reward Measure Different Things

A settlement is the amount a company agrees to pay. A government recovery is the money collected. A whistleblower reward is a share of the recovery from the whistleblower case.

The Pfizer announcement assigned $668,514,830 to the federal government and $331,485,170 to state Medicaid programs.

Exclusion Reaches the Business Behind the Payment

Exclusion affects access to federal health care program reimbursement. It can therefore reach the company’s ability to keep doing business with Medicare and Medicaid, beyond the amount negotiated in a settlement.

There is also a direct exclusion route for pricing misconduct. The Medicaid Services Investment and Accountability Act of 2019 added authority covering a manufacturer that knowingly misclassifies a drug, knowingly fails to correct the classification or knowingly supplies false drug-pricing information. Price reporting can therefore affect more than the rebate balance.

Corporate Integrity Agreements Change How the Company Operates

A corporate integrity agreement can put continuing obligations inside the departments where the conduct occurred. Pfizer’s agreement required annual compliance certifications by senior executives and board members, along with public disclosures. The company also agreed to procedures and reviews intended to detect conduct like that behind its settlement.

GlaxoSmithKline’s 2012 resolution changed sales incentives. Its agreement barred rewarding or disciplining sales representatives who worked with prescribers, and their direct managers, based on how much their territories or districts sold. The restriction reached the incentive behind the sales call.

These agreements can reach speaker budgets, attendance records, monitoring and the people who certify that a business unit follows the rules. For an employee, those are recognizable parts of the job: the event approval, the expense record and the sign-off above it.

The obligations carry consequences of their own. In Eli Lilly’s settlement announcement, the government described exclusion for a material breach of the integrity agreement and monetary penalties for less significant breaches.

Why the Penalty Changes With the Calendar

False Claims Act per-claim penalties have risen through inflation adjustments. The statute’s 1986 figures were $5,000 to $10,000 per claim. Later adjustments increased the price of each false bill, on top of damages for the government’s loss.

The dates of the conduct and the penalty assessment determine which range applies. The Justice Department kept its latest range unchanged for 2026 because there was no cost-of-living adjustment that year.

What the Scheme Looks Like Inside a Drug Company

The records behind a civil penalty often begin as ordinary commercial records. Speaker approvals connect payments to prescribers. Hospital contracts identify discounts. Pricing submissions determine what a manufacturer tells the government it owes.

Speaker Payments Connected to Prescriptions

A claim resulting from an Anti-Kickback Statute violation can become a false claim. A payment made to induce prescribing can therefore lead to a civil case over the government-funded prescriptions that result.

The whistleblower complaint against Forest Pharmaceuticals alleged that managers directed representatives to alter attendance records when speaker programs failed to meet company policies:

The sign-in sheet was supposed to document the meeting. The complaint alleges that staff changed it to make the meeting appear to satisfy the rules. It also alleges that internal reports identified providers with Medicare and Medicaid patients and tracked prescribing.

Copay Funding That Steers the Prescription

A manufacturer can also fund a patient’s copay through a foundation. The payment travels through the charity, but the manufacturer benefits when the patient fills its prescription.

In its 2017 United Therapeutics settlement announcement, the Justice Department alleged that the company used a purportedly independent foundation to pay Medicare patients’ copays for pulmonary arterial hypertension drugs. The civil allegation concerned the connection between manufacturer funding and reimbursed prescriptions.

That is a different money trail from a speaking fee.

Drug Rebate Fraud Penalties Begin With the Pricing Data

Drug rebate fraud penalties can arise from false pricing information and the Medicaid rebates it reduces. Manufacturers report average manufacturer price and Best Price to the government. Those inputs help determine the rebate owed for drugs Medicaid pays for.

Best Price takes account of qualifying discounts and rebates, including discounts allocated across bundled products. A hospital contract can therefore affect what the manufacturer owes Medicaid long after the hospital has received its discount.

The 2016 Wyeth and Pfizer rebate settlement concerned alleged discounts bundled across oral and intravenous Protonix. The government alleged that Wyeth wanted hospitals to start patients on the oral drug because patients were likely to keep taking it after discharge, when payers including Medicaid would pay nearly full price. It alleged that Wyeth hid the bundled hospital discounts from Medicaid’s Best Price calculation.

In the government’s account, the hospital discount helped win business after discharge. The alleged omission reduced what Medicaid received back. A managed-markets employee could recognize the contract, while a government-pricing employee could recognize how it was treated in the submission.

Drug classification creates another route. In Mylan’s 2017 EpiPen settlement, the government alleged that reporting EpiPen as a generic let the company avoid the corresponding brand-drug rebate obligations while increasing private-market prices. The product’s classification was part of the payment calculation.

Medicaid’s reporting rules also carry separate civil monetary penalties for late information and knowingly false price or product information. Legislation enacted on April 18, 2019 added specific remedies for drug misclassification, including recovery of underpaid rebates, penalties for knowing misclassification and authority to correct the classification. The company’s contract, reported price and reported drug category can each affect a different part of the same public payment.

Manufacturing Failures Connected to Reimbursement

Manufacturing conduct can reach the civil False Claims Act when a company causes government claims for defective drugs. GlaxoSmithKline’s 2010 Cidra plant settlement addressed civil allegations involving adulterated Kytril, Bactroban, Paxil CR and Avandamet.

The civil allegations connected the drugs leaving the plant to the bills government programs paid.

What Historical Pharmaceutical Penalties Show

Civil pharmaceutical recoveries have been substantial even when examined separately. Public Citizen’s 2018 study of pharmaceutical industry penalties reported at least $12.1 billion in federal False Claims Act payments by the industry during fiscal 1991 through fiscal 2017, compared with $5.3 billion from the defense industry over the same period.

The study also found that overcharging government health programs, mainly pricing fraud against state Medicaid programs, appeared in more settlements than any other violation. Its account of those cases explains why the manufacturer’s price data matters:

The study shows the importance of pricing cases alongside promotion cases: a number supplied by the drug company can determine how much public money changes hands.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

In the Pfizer case, six whistleblowers whose lawsuits triggered the investigation were to receive more than $102 million from the federal civil recovery.

When You Know What Went Into the Number

If you know why a speaker was paid, a discount was omitted or a rebate calculation stayed wrong, speak with our whistleblower experts about the decisions behind it. We work with you to connect those decisions to the government’s payments and build your strongest pharmaceutical whistleblower case. We bring in pharmaceutical fraud whistleblower lawyers who understand prescribing incentives and government pricing, and stay beside you through the process.